Improving Safety in Phase I Trials - Planning Your Early Phase Development?

Posted:
24
April 2007

Join Richmond Pharmacology at Europe's leading Exploratory Clinical Development Congress13-16 May 2008, Earls Court Conference Centre, LondonAs the UK's largest Early Phase CRO, uniquely based in 2 acute NHS teaching hospitals, Richmond Pharmacology Ltd is proud to be an Associate Sponsor of the upcoming Exploratory Clinical Development Congress.Dr. Jorg Taubel, Managing Director of RPL, will be presenting on Day One, 14th May at 10.30am, on "Managing Risk in Early Development" and as an experienced trialist will be part of the panel discussion on "Improving the Safety of Phase I trials".We are delighted to be able to offer you a 15% discount on any delegate packages to attend this conference - please see below for details.In 2008, early clinical development remains at a critical stage. The transition to First In Man has crucial regulatory, scientific and operational issues that need to be confronted head on in order to avoid high costs and high profile product failures. Safety concerns continue to dominate and following recommendations from the ESG Working Group, the ABPI has revised its guidelines for Phase I trials.The second Exploratory Clinical Development Congress will address the critical issues in achieving seamless First In Man studies and will also provide advice on how to conduct effective studies that allow you to make the right decision early on in clinical development.Topics to be addressed at the 2008 Congress include:

  • Improving the safety of Phase I Trials - Where are we now?
  • Creating a smooth transition between preclinical and first use in man
  • Enhanced Phase I strategies
  • Managing risk in early development
  • Choosing the right dosage form
  • Biomarkers in early development
  • QT in Phase I
  • Protocol design for Phase I trials
  • The role of experimental medicine
  • Translational medicine and the rational design of exploratory studies

15% discount on attendance at this conference - If you wish to accept this offer, please contact Health Network Communications directly on: +44(0)20 7608 7056 or email: kwilliams@healthnetworkcommunications.com, quoting Richmond Pharmacology.We will be exhibiting on Stand 2 and would like to extend a warm invitation to join us on the stand to discuss your upcoming Early Phase outsourcing requirements.We look forward to meeting you at the Congress,Best regards,Dr. Jorg Taubel MFPM, MDManaging Director

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Novel rate-controlled fentanyl patch shows promise in phase I clinical trial

April 1, 2021
Our expertise in ethnic differences and access to over 12,000 first generation Japanese volunteers accelerated our ability to provide robust clinical trial data to support future applications of new chronic pain medicines to the Japanese drug market.
Read more

A new era for UK-Japanese scientific relations

March 23, 2021
Dr Taubel uses his experience of conducting more than 60 Japanese bridging studies to explain why the deal is of strategic importance to the UK and highlights the scientific requirements for conducting successful Japanese trials abroad
Read more

Richmond Pharmacology’s local MP Neil Coyle calls on the Government to evaluate the potential of using Clinical Research Organisations.

February 3, 2021
Richmond Pharmacology has offered its services to the Government and the NHS as an additional vaccine site in London
Read more